Charles River Laboratories - 15 Year Stock Price History | CRL
Historical daily share price chart and data for Charles River Laboratories since 2011 adjusted for splits and dividends. The latest closing stock price for Charles River Laboratories as of June 17, 2026 is 182.34.
- The all-time high Charles River Laboratories stock closing price was 458.30 on September 24, 2021.
- The Charles River Laboratories 52-week high stock price is 228.88, which is 25.5% above the current share price.
- The Charles River Laboratories 52-week low stock price is 144.26, which is 20.9% below the current share price.
- The average Charles River Laboratories stock price for the last 52 weeks is 174.14.
| Charles River Laboratories Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 180.1264 | 202.4200 | 226.7700 | 149.9300 | 182.3400 | -8.59% |
| 2025 | 160.4040 | 182.6400 | 203.6600 | 99.7500 | 199.4800 | 8.06% |
| 2024 | 216.1551 | 234.2500 | 273.4300 | 178.5800 | 184.6000 | -21.91% |
| 2023 | 206.8410 | 218.4000 | 259.9200 | 164.5200 | 236.4000 | 8.49% |
| 2022 | 246.3805 | 362.1100 | 362.1100 | 182.4400 | 217.9000 | -42.17% |
| 2021 | 354.9112 | 249.6700 | 458.3000 | 249.6700 | 376.7800 | 50.80% |
| 2020 | 189.2381 | 153.8900 | 252.6200 | 98.9000 | 249.8600 | 63.56% |
| 2019 | 134.9265 | 111.0900 | 152.7600 | 104.8200 | 152.7600 | 34.97% |
| 2018 | 116.1663 | 110.6500 | 137.2300 | 98.1900 | 113.1800 | 3.41% |
| 2017 | 97.1831 | 76.5300 | 118.0900 | 76.5300 | 109.4500 | 43.65% |
| 2016 | 79.1136 | 78.2500 | 88.4400 | 67.1000 | 76.1900 | -5.22% |
| 2015 | 72.9128 | 63.8800 | 84.2000 | 61.5900 | 80.3900 | 26.32% |
| 2014 | 58.2804 | 52.8800 | 65.5900 | 50.7400 | 63.6400 | 19.98% |
| 2013 | 45.2635 | 38.0400 | 53.3600 | 38.0400 | 53.0400 | 41.55% |
| 2012 | 35.7702 | 27.7500 | 41.2400 | 27.3900 | 37.4700 | 37.10% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.667B | $4.015B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.187B | 24.31 |
| HCA Healthcare (HCA) | United States | $110.772B | 17.53 |
| CVS Health (CVS) | United States | $101.670B | 11.75 |
| Elevance Health (ELV) | United States | $68.432B | 10.33 |
| Cencora (COR) | United States | $62.409B | 19.63 |
| Natera (NTRA) | United States | $27.358B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.501B | 15.87 |
| DiDi Global (DIDIY) | China | $18.026B | 15.96 |
| Viatris (VTRS) | United States | $15.685B | 5.71 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.535B | 0.00 |
| Medpace Holdings (MEDP) | United States | $14.094B | 32.26 |
| BioMerieux (BMXMF) | France | $12.476B | 0.00 |
| Solventum (SOLV) | United States | $11.408B | 10.78 |
| Revvity (RVTY) | United States | $10.039B | 17.71 |
| BrightSpring Health Services (BTSG) | United States | $8.774B | 43.59 |
| ICON (ICLR) | Ireland | $8.626B | 8.56 |
| CochLear (CHEOY) | Australia | $8.030B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $6.905B | 0.00 |
| HealthEquity (HQY) | United States | $6.586B | 23.20 |
| Bausch + Lomb (BLCO) | Canada | $5.877B | 32.98 |
| GETINGE (GNGBY) | Sweden | $5.626B | 17.96 |
| Avantor (AVTR) | United States | $5.388B | 8.68 |
| PACS (PACS) | United States | $5.304B | 27.44 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.101B | 0.00 |
| Sotera Health (SHC) | United States | $4.380B | 19.95 |
| Alignment Healthcare (ALHC) | United States | $4.188B | 0.00 |
| Concentras Parent (CON) | United States | $2.818B | 16.12 |
| Organon (OGN) | United States | $2.299B | 2.57 |
| Amplifon S.p.A (AMFPF) | Italy | $2.275B | 13.27 |
| Pediatrix Medical (MD) | United States | $1.782B | 11.11 |
| Establishment Labs Holdings (ESTA) | United States | $1.765B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.746B | 42.28 |
| Surgery Partners (SGRY) | United States | $1.671B | 41.65 |
| Sonida Senior Living (SNDA) | United States | $1.544B | 0.00 |
| Ardent Health (ARDT) | United States | $1.345B | 5.70 |
| Progyny (PGNY) | United States | $1.277B | 25.08 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.113B | 164.00 |
| Teladoc Health (TDOC) | United States | $0.920B | 0.00 |
| CareDx (CDNA) | United States | $0.822B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.750B | 12.17 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Nutex Health (NUTX) | United States | $0.704B | 11.25 |
| Omada Health (OMDA) | United States | $0.672B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.604B | 99.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Embecta (EMBC) | United States | $0.524B | 2.92 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| CryoPort (CYRX) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.435B | 4.70 |
| SBC Medicals (SBC) | United States | $0.426B | 8.47 |
| Forward Industries (FWDI) | United States | $0.375B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.349B | 0.00 |
| Agilon Health (AGL) | United States | $0.316B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.309B | 0.00 |
| Oncology Institute (TOI) | United States | $0.304B | 0.00 |
| So-Young (SY) | China | $0.262B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Biodesix (BDSX) | United States | $0.133B | 0.00 |
| Beauty Health (SKIN) | United States | $0.115B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.080B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.077B | 0.00 |
| DocGo (DCGO) | United States | $0.051B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Pomdoctor - (POM) | China | $0.031B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.026B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.015B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Lifeward (LFWD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.005B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |